Regulation of angiogenesis and angiogenic factors by cardiovascular medications

Current Pharmaceutical Design

Volumn 13, Issue 20, 2007, Pages 2113-2117

  Miura, Shin Ichiro ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin converting enzyme inhibitor; Angiotensin II type 1 receptor blocker; Calcium channel blocker; Coronary artery disease; Coronary collateral circulation; Endothelium; Statins

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ANGIOGENIC FACTOR; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; BRADYKININ B2 RECEPTOR; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CARDIOVASCULAR AGENT; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRIC ACID; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KININOGEN; LOSARTAN; NIFEDIPINE; NITRIC OXIDE; NORADRENALIN; PERINDOPRIL; PROBUCOL; QUINAPRILAT; SIMVASTATIN; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; BONE MARROW CELL; CAUSE OF DEATH; CELL TRANSPLANTATION; COLLATERAL CIRCULATION; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE MODEL; DRUG ACTIVITY; ENDOTHELIUM; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LIMB ISCHEMIA; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR AGENTS; CHOLESTEROL ESTER TRANSFER PROTEINS; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 34447262591     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207781039724     Document Type: Review

References (66)

1. Scheinowitz M. Therapeutic myocardial angiogenesis: past, present and future. Mol Cell Biochem 2004; 264: 75-83.
2. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 1999; 103: 1231-6.
3. van Royen N, Piek JJ, Buschmann I, Hoefer I, Voskuil M, Schaper W. Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease. Cardiovasc Res 2001; 49: 543-53. Review.
4. Giordano FJ, Ping P, McKirnan MD, Nozaki S, DeMaria AN, Dillmann WH, et al. Intrucoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 1996; 2: 534-9.
5. Tio RA, Tkebuchava T, Scheuermann TH, Lebherz C, Magner M, Kearny M, et al. Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral flow to ischemic myocardium. Hum Gene Tlier 1999; 10: 2953-60.
6. Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002; 105: 1291-7.
7. Nelissen-Vrancken HJ, Debets JJ, Snoeckx LH, Daemen MJ, Smits JF. Tim-related normalization of maximal coronary flow in isolated perfused hearts of rates with myocardial infarction. Circulation 1996; 93: 349-55.
8. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevent cardiomyocyte aptosis, reduces remodeling and improves cardiac function. Nat Med 2001; 7: 430-6.
9. Miura S, Fujino M, Matsuo Y, Kawamura A, Tanigawa H, Nishikawa H, et al. High Density Lipoprotein-induced angiogenesis requires the activation of Ras/MAP kinase in human coronary artery endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 802-8.
10. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6: 1004-10.
11. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation 2002; 105: 739-45.
12. Asahara T, Masuda H, Takahashi T, Kalka. C, Pastore C, Silver M, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovasculari-zation. Circ Res 1999; 85: 221-8.
13. Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001; 108: 399-405.
14. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001; 108: 391-7.
15. Landmesser U, Engberding N, Bahlmann FH, Schaefer A, Wiencke A, Heineke A, et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 2004; 110: 1933-39.
16. Miura S, Tanigawa H, Matsuo Y, Fujino M, Kawamura A, Saku K. Ras/ Rafl-depedent signal in sphingosine-1-phosphate-induced tube formation in human coronary artery endothelial cells. Biochem Biophys Res Commun 2003 306: 924-9.
17. Grewal T, Evans R, Rentero C, Tebar F, Cubells L, de Diego I, et al. High density lipoprotein-induced signaling of the MAPK pathway involves scavenger receptor type BI-mediated activation of Ras. J Biol Chem 2003; 278: 16478-81.
18. Nishikawa H, Miura S, Zhang B, Shimomura H, Arai H, Tsuchiya Y, et al. Pravastatin promotes coronary collateral circulation in patients with coronary artery disease. Coron Artery Dis 2002; 13: 377-81.
19. Pourati I, Kimmelstiel C, Rand W, Karas RH. Statin use is associated with enhanced collateralization of severely diseased coronary arteries. Am Heart J 2003; 146: 876-81.
20. Zbinden S, Brunner N, Wustmann K, Billinger M, Meier B, Seiler C. Effect of statin treatment on coronary collateral flow in patients with coronary artery disease Heart 2004; 90: 448-9.
21. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23: 160-7.
22. Miura S, Matsuo Y, Kawamura A, Saku K. JTT-705 blocks cell proliferation and angiogenesis through p38 kinase/p27kip1 and Ras/p21waf1 pathways. Atherosclerosis 2005; 182: 267-75.
23. Kaneko T, Fujii S, Matsumoto A, Goto D, Makita N, Hamada J, et al. Induction of tissue factor expression in endothelial cells by basic fibroblast growth factor and its modulation by fenofibric acid. Thromb J 2003; 1: 6.
24. Nishimura G, Yanoma S, Mizuno H, Kawakami K, Tsukuda M. An antioxidant, probucol, induces anti-angiogenesis and apoptosis in athymic nude mouse xenografted human head and neck squamous carcinoma cells. Jpn J Cancer Res 1999; 90: 1224-30.
25. Suzuki H, Kanno Y. Efficacy of candesartan on outcome in saitama trial (E-COST) group. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens Res 2005; 28: 307-14.
26. Tamarat R, Silvestre JS, Kubis N, Benessiano J, Duriez M, deGasparo M, et al. Endothelial nitric oxide synthase lies downstream from angiotensin II-induced angiogenesis in ischemic hindlimb. Hypertension 2002; 39: 830-5.
27. Fujiyama S, Matsubara H, Nozawa Y, Maruyama K, Mori Y, Tsutsumi Y, et al. Angiotensin AT(1) and AT(2) receptors differently regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circ Res 2001; 88: 22-9.
28. Otani A, Takagi H, Suzuam Y, Honda Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 1998; 82: 619-28.
29. Chua CC, Hamdy RC, Chua BH. Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta 1998; 1401: 187-94.
30. Imanishi T, Hano T, Nishio I. Angiotensin II potentiates vascular endothelial growth factor-induced proliferation and network formation of endothelial progenitor cells. Hypertens Res 2004; 27: 101-8.
31. Sasaki K, Murohara T, Ikeda H, Sugaya T, Shimada T, Shintani S, et al. Evidence for the importance of angiotensin II type1 receptor in ischemia-induced angiogenesis. J Clin Invest 2002; 109: 603-11.
32. Schuijt MP, de Vries R, Saxena PR, Schalekamp MA, Danser AH. Angiotensin AT(1) receptor signaling modulates reparative angio-genesis induced by limb ischemia. Br J Pharmacol 2002; 135: 87-92.
33. Munzenmaier DH, Greene AS. Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. Hypertension 1996; 27: 760-5.
34. de Boer RA, Pinto YK, Suurmeijer AJ, Pokharel S, Scholtens E, Humler M, et al. Increased expression of cardiac angiotensin II type1 (AT1) receptors decrease myocardial microvessel density after experimental myocardial infarction. Cardiovasc Res 2003; 57: 434-42.
35. Cameron NE, Cotter MA, Robertson S. Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats. Diabetologia 1992; 35: 12-8.
36. Maxfield EK, Cameron NE, Cotter MA, Dines KC. Angiotensin II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneurial angiogenesis in streptozotocin-diabetic rats and nerve function. Diabetologia 1993; 36: 1230-7.
37. Vetti G, Cigola E, Lagrasta C, Ricci R, Quaini F, Monopoli A, et al. Spirapril prevents left ventricular hypertrophy, decreases myocardial damage and promotes angiogenesis in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1993; 21: 362-70.
38. Clozel JP, Kuhn H, Hefti F. Effects of chronic ACE inhibition on cardiac hypertrophy and coronary vascular reserve in spontaneously hypertensive rats with developed hypertension. J Hypertens 1989; 7:267-75.
39. Gohlke P, Kuwer I, Schnell A, Amann K, Mall G, Unger T. Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats. Hypertension 1997; 29: 478-82.
40. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angio-genesis. Nature 1992; 359: 843-5.
41. Brogi E, Wu T, Namiki A, Isner JM. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 1994; 90: 649-52.
42. Fabre JE, Rivard A, Magner M, Silver M, Isner JM. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation 1999; 99: 3043-9.
43. Miura S, Matsuo Y, Saku K. Transactivation of KDR/Flk-1 by the B2 receptor induces tube formation in human coronary endothelial cells. Hypertension 2003; 41: 1118-23.
44. Takai S, Jin D, Sakaguchi M, Muramatsu M, Ishii K, Kirimura K, et al. Comparative effects of candesartan and amlodipine in a monkey atherosclerotic model. Hypertens Res 2004; 27: 517-22.
45. Emanueli C, Bonaria Salis M, Stacca T, Pintus G, Kirchmair R, Isner JM, et al. Targeting kinin B(1) receptor for therapeutic neovascularization. Circulation 2002; 105: 360-6.
46. Parenti A, Morbidelli L, Ledda, F, Granger HJ, Ziche M. The bradykinin/ B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J 2001; 15: 1487-9.
47. Silvestre JS, Bergaya S, Tamarat R, Duriez M, Boulanger CM, Levy BI. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res 2001; 89: 678-83.
48. Siragy HM, Senbonmatsu T, Ichiki T, Inagami T, Carey RM. Increased renal vasodilator prostanoids prevent hypertension in mice lacking the angiotensin subtype-2 receptor. J Clin Invest 1999; 104: 181-8.
49. Emanueli C, Salis MB, Van Linthout S, Meloni M, Desortes E, Silvestre JS, et al. Akt/protein kinase B and endothelial nitric oxide synthase mediate muscular neovascularization induced by tissue kallikrein gene transfer. Circulation 2004; 110: 1638-44.
50. Levy BI, Benessiano J, Henrion D, Caputo L, Heymes C, Duriez M, et al. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest 1996; 98: 418-25.
51. Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz J, Riede UN, et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994; 89: 2273-82.
52. Sladek T, Sladkova J, Kolar F, Papousek F, Cicutti N, Korecky B, et al. The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats. Cardiovasc Res 1996; 31: 568-76.
53. Imaizumi S, Miura S, Nishikawa H, Iwata, A, Zhang B, Kawamura A, et al. Angiotensin II type 1 receptor blocker does not promote coronary collateral circulation in patients with coronary artery disease. Hypertens Res 2006; 29: 135-41.
54. Miura S, Nishikawa H, Zhang B, Matuo Y. Angiotensin-converting enzyme inhibitor promotes coronary collateral circulation in patients with coronary artery disease. Circ J 2003; 67: 535-8.
55. Walsh DA, Hu DE, Wharton J, Catravas JD, Blake DR, Fan TP. Sequential development of angiotensin receptors and angiotensin I converting enzyme during angiogenesis in the rat subcutaneous sponge granuloma. Br J Pharmacol 1997; 120: 1302-11.
56. Miura S, Fujino M, Matsuo Y, Tanigawa H, Saku K. Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via KDR/Flk-1/NO pathway. Hypertens Res 2005; 28: 147-53.
57. Fukuo K, Yang J, Yasuda O, Mogi M, Suhara T, Sato N, et al. Nifedipine indirectly upregulates superoxide dismutase expression in endothelial cells via vascular smooth muscle cell-dependent pathways. Circulation 2002; 106: 356-61.
58. Orth SR, Nobiling R, Bonisch S, Ritz E. Inhibitory effect of calcium channel blockers on human mesangial cell growth: evidence for actions independent of L-type Ca2+ channels. Kidney Int 1996; 49: 868-79.
59. Hempel A, Lindschau C, Maasch C, Mahn M, Bychkov R, Noll T, et al. Calcium antagonists ameliorate ischemia-induced endothelial cell permeability by inhibiting protein kinase C. Circulation 1999; 99: 2523-9.
60. Kilian JG, Keech A, Adams MR, Celermajer DS. Coronary collateralization: determinants of adequate distal vessel filling after arterial occlusion. Coron Artery Dis 2002; 13: 155-9.
61. Weil J, Benndorf R, Fredersdorf S, Griese DP, Eschenhagen T. Norepinephrine upregulates vascular endothelial growth factor in rat cardiac myocytes by a paracrine mechanism. Angiogenesis 2003; 6: 303-9.
62. Dedkov EI, Christensen LP, Weiss RM, Tomanek RJ. Reduction of heart rate by chronic beta1 -adrenoceptor blockade promotes growth of arterioles and preserves coronary perfusion reserve in postinfarcted heart. Am J Physiol Heart Circ Physiol 2005; 288: H2684-93.
63. Da Silva-Azevedo L, Baum O, Zakrzewicz A, Pries AR. Vascular endothelial growth factor is expressed in endothelial cells isolated from skeletal muscles of nitric oxide synthase knockout mice during prazosin-induced angiogenesis. Biochem Biophys Res Commun 2002; 297: 1270-6.
64. Bainbridge J, Sivakumar B, Paleolog E. Angiogenesis as a therapeutic target in arthritis: lessons from oncology. Curr Pharm Des 2006; 12(21): 2631-44.
65. Shimada, Y. Does Angiotensin converting enzyme inhibitor protect the heart in cardiac surgery? From laboratory to operating room: clinical application of experimental study. Curr Pharm Des 2006; 12(4): 517-26.
66. Su JB. Kinins and cardiovascular diseases. Curr Pharm Des 2006; 12(26): 3423-35.